Menu
The AHA raised concerns that October 2024 federal guidance on Medicare drug price negotiations may allow drugmakers to “wrongly justify fundamental changes to the 340B program.”

CMS Finalizes Next Medicare Drug Negotiation Guidance Without Resolving Key Concerns of 340B Stakeholders

William Newton, Editor-in-Chief 340B Report Views
Federal regulators issued final guidance for the next round of Medicare drug price negotiations yesterday but did not propose remedies [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Post Navigation

Webinar—Neutral 340B Clearinghouse: Ready, Set, Now Go!

Arkansas Begins Enforcement Against AstraZeneca for Allegedly Violating Contract Pharmacy Access Law

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Site Footer Live